MHRA Approves BetaGlue Therapeutics’ Clinical Trial Application for YntraDose(TM) in unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC)
MHRA Approves BetaGlue Therapeutics' Clinical Trial Application for YntraDose(TM) in unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC) GlobeNewswire November 12, 2025 MILAN, Nov. 12, 2025 (GLOBE NEWSWIRE) — BetaGlue(R) Therapeutics (“BetaGlue” or the “Company”) a clinical-stage oncology company developing an innovative radiotherapy solution for the targeted treatment of solid tumours, announced today that the Medicines and […]